^
    2d
    A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patients (clinicaltrials.gov)
    P4, N=10, Active, not recruiting, Sun Pharmaceutical Industries Limited | Trial completion date: Nov 2025 --> Mar 2026 | Trial primary completion date: Nov 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    2d
    PILLAR: Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=26, Completed, University of California, San Francisco | Trial completion date: Jan 2027 --> Oct 2025 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    |
    apalutamide
    3d
    Exploring the interplay of electron density distribution and electrostatic potential in the interaction of nilutamide and flutamide with androgen receptors using quantum crystallography. (PubMed, RSC Adv)
    The results of the high-resolution X-ray experiment and the advanced computational charge density study of NIL and FLU allows us to understand drug binding and is useful to relate their differing biological effects and toxicities at the electronic level. This information pertains to the design of a new potential androgen inhibitor with improved binding affinity and fewer side effects.
    Journal
    |
    AR (Androgen receptor)
    |
    flutamide • nilutamide
    7d
    Small-molecule modulators of the androgen receptor N-terminal domain: Advances in medicinal chemistry for prostate cancer. (PubMed, Eur J Med Chem)
    Advances in screening platforms and the optimization of structure-activity relationships are beginning to address the challenges of targeting disordered protein domains. With agents like EPI-7386 entering clinical evaluation and others advancing through preclinical development, AR NTD-targeted therapies represent a promising avenue to overcome resistance in castration-resistant prostate cancer (CRPC), potentially in combination with existing LBD-directed treatments to achieve more durable disease control.
    Review • Journal
    |
    AR (Androgen receptor)
    |
    AR splice variant 7
    |
    masofaniten (EPI-7386)
    10d
    A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer (clinicaltrials.gov)
    P2, N=30, Recruiting, Memorial Sloan Kettering Cancer Center
    New P2 trial
    |
    Firmagon (degarelix)
    16d
    Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, Rutgers, The State University of New Jersey | Trial completion date: Nov 2026 --> Jun 2027 | Trial primary completion date: Nov 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    abiraterone acetate • prednisone • apalutamide
    23d
    S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer (clinicaltrials.gov)
    P3, N=1313, Completed, SWOG Cancer Research Network | Active, not recruiting --> Completed | Trial completion date: Oct 2027 --> Sep 2025
    Trial completion • Trial completion date
    |
    bicalutamide • orteronel (TAK 700)
    25d
    Identifying myosin heavy chain 11 as a predictive biomarker of prostate cancer progression and antiandrogen resistance. (PubMed, Oncol Lett)
    Using the GSE211781 dataset from the Gene Expression Omnibus database, the present study analyzed RNA-sequencing data from lymph node carcinoma of the prostate (LNCaP) cell lines resistant to three antiandrogen drugs: Bicalutamide, enzalutamide and apalutamide. Functional assays in C4-2 and LNCaP cells further indicated that MYH11 modulates sensitivity to bicalutamide and enzalutamide. Collectively, the present study findings suggest that MYH11 may serve as a potential predictive biomarker of PCa development and antiandrogen drug resistance in the future.
    Journal
    |
    MYH11 (Myosin Heavy Chain 11)
    |
    Xtandi (enzalutamide) • bicalutamide • apalutamide
    1m
    A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male Participants (clinicaltrials.gov)
    P1, N=42, Recruiting, Celgene | Not yet recruiting --> Recruiting
    Enrollment open
    |
    itraconazole • rifampicin
    1m
    CC-94676-PCA-001: Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=131, Completed, Celgene | Active, not recruiting --> Completed | N=250 --> 131 | Trial completion date: Dec 2026 --> Oct 2025
    Trial completion • Enrollment change • Trial completion date
    1m
    SCALP1: A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (clinicaltrials.gov)
    P3, N=703, Active, not recruiting, Cassiopea SpA | Recruiting --> Active, not recruiting | Trial completion date: Apr 2025 --> Dec 2025 | Trial primary completion date: Oct 2024 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    1m
    A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2) (clinicaltrials.gov)
    P3, N=762, Completed, Cassiopea SpA | Recruiting --> Completed | Trial completion date: Mar 2025 --> Jul 2025 | Trial primary completion date: Aug 2024 --> Jul 2025
    Trial completion • Trial completion date • Trial primary completion date